GERMANTOWN, Md., Jan. 19, 2018 /PRNewswire/ -- Intrexon
Corporation (NYSE: XON) announced today the closing of its
previously announced underwritten public offering of common stock.
Intrexon sold 6,900,000 shares of its common stock at a public
offering price of $12.50 per share,
including the exercise in full by the underwriters of their option
to purchase an additional 900,000 shares of common stock.
Gross proceeds to Intrexon from the offering are expected to be
approximately $86 million before
deducting the underwriting discount and other offering expenses
payable by Intrexon.
JMP Securities LLC acted as sole book-running manager and Stifel
acted as lead manager for the offering. Northland Capital Markets
acted as co-manager for the offering.
The public offering was made pursuant to an automatic shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (SEC) and became effective
on September 1, 2017. A final
prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC and is available on the
website of the SEC at www.sec.gov. Copies of the final
prospectus supplement and accompanying base prospectus relating to
the offering may also be obtained from JMP Securities LLC, 600
Montgomery Street, Suite 1100, San
Francisco, California 94111, Attention: Prospectus
Department, by calling +1 (415) 835-8985, or by email at
syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Intrexon Corporation
Intrexon Corporation
(NYSE: XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve
the quality of life and the health of the planet. Intrexon's
integrated technology suite provides its partners across diverse
markets with industrial-scale design and development of complex
biological systems delivering unprecedented control, quality,
function, and performance of living cells.
Trademarks
Intrexon, Powering the Bioindustrial
Revolution with Better DNA, and Better DNA are trademarks of
Intrexon and/or its affiliates. Other names may be trademarks of
their respective owners.
Forward-Looking Safe Harbor Statement:
This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which involve risks and uncertainties, including statements
regarding the proposed public offering. Various factors may cause
differences between Intrexon's expectations and actual results,
including risks and uncertainties associated with market conditions
and the satisfaction of customary closing conditions related to the
proposed offering. More information about potential factors that
could affect Intrexon's business and financial results is contained
in its annual report on Form 10-K, its quarterly reports on Form
10-Q and other filings with the SEC. Intrexon does not intend, and
undertakes no duty, to update this information to reflect future
events or circumstances.
For more information about Intrexon Corporation,
contact:
Investor Contact:
Thomas Shrader, PhD
Vice President, Communications & Strategy
Intrexon Corporation
investors@intrexon.com
Corporate Contact:
Marie Rossi, PhD
Director, Technical Communications
Intrexon Corporation
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/intrexon-announces-closing-of-public-offering-of-common-stock-and-exercise-of-option-by-underwriters-300585279.html
SOURCE Intrexon Corporation